Kadmon Pharms Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for KADMON PHARMS LLC
KADMON PHARMS LLC has one approved drug.
There are five US patents protecting KADMON PHARMS LLC drugs.
There are fifty-two patent family members on KADMON PHARMS LLC drugs in twenty-nine countries and one supplementary protection certificate in one country.
Summary for Kadmon Pharms Llc
| International Patents: | 52 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Kadmon Pharms Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kadmon Pharms Llc | REZUROCK | belumosudil mesylate | TABLET;ORAL | 214783-001 | Jul 16, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Kadmon Pharms Llc | REZUROCK | belumosudil mesylate | TABLET;ORAL | 214783-001 | Jul 16, 2021 | RX | Yes | Yes | 8,357,693 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Kadmon Pharms Llc | REZUROCK | belumosudil mesylate | TABLET;ORAL | 214783-001 | Jul 16, 2021 | RX | Yes | Yes | 10,696,660 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Kadmon Pharms Llc | REZUROCK | belumosudil mesylate | TABLET;ORAL | 214783-001 | Jul 16, 2021 | RX | Yes | Yes | 12,097,202 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Kadmon Pharms Llc | REZUROCK | belumosudil mesylate | TABLET;ORAL | 214783-001 | Jul 16, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Kadmon Pharms Llc | REZUROCK | belumosudil mesylate | TABLET;ORAL | 214783-001 | Jul 16, 2021 | RX | Yes | Yes | 10,183,931 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Kadmon Pharms Llc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 113773308 | ⤷ Start Trial |
| Hungary | E059305 | ⤷ Start Trial |
| Australia | 2022469413 | ⤷ Start Trial |
| Ecuador | SP077836 | ⤷ Start Trial |
| Slovenia | 2903618 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2014055996 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Kadmon Pharms Llc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2903618 | SPC/GB22/068 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: BELUMOSUDIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK PLGB 53904/0001-0001 20220707 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
